Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease

May 31, 2020 By The ASCO Post Staff

Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).

Related Content